Show simple item record

dc.contributor.authorMandrekar, Pranoti
dc.contributor.authorCardinale, Vincenzo
dc.date2022-08-11T08:09:50.000
dc.date.accessioned2022-08-23T16:45:11Z
dc.date.available2022-08-23T16:45:11Z
dc.date.issued2018-04-25
dc.date.submitted2018-06-15
dc.identifier.citation<p>Hepatol Commun. 2018 Apr 25;2(5):481-483. doi: 10.1002/hep4.1189. eCollection 2018 May. <a href="https://doi.org/10.1002/hep4.1189">Link to article on publisher's site</a></p>
dc.identifier.issn2471-254X (Linking)
dc.identifier.doi10.1002/hep4.1189
dc.identifier.pmid29761164
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40633
dc.description.abstractCholangiocarcinoma (CCA), a heterogeneous group of malignancy arising at any level of the biliary tree based on their anatomical location, is classified into intrahepatic (iCCA), perihilar, and distal subtypes. iCCA, which arises distally to the second‐order bile ducts, is a highly heterogeneous and aggressive malignancy with overall poor prognosis. The rate of iCCA is increasing rapidly, particularly in Western countries; however, its precise etiology and pathogenesis remain elusive.1 While surgical resection is the first line of treatment, liver transplantation is the potential curative treatment for unresectable tumors in patients with iCCA, and posttransplantation 5‐year survival rates are 51% in these patients. Currently, there are no curative medical therapies or targeted molecular therapies approved for use in iCCA. The complex plethora of cell types, extracellular matrix, and soluble factors that influence tumor progression should be considered to understand its pathogenesis and to devise effective strategies for its clinical management.1 Furthermore, identification of biomarker signatures relevant to disease progression and aggressiveness may not only aid in diagnosis but also have prognostic value that will help build a precision approach for the treatment of iCCA....
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29761164&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDigestive System Diseases
dc.subjectGastroenterology
dc.subjectHepatology
dc.subjectNeoplasms
dc.titlePeriostin and mesothelin: Potential predictors of malignant progression in intrahepatic cholangiocarcinoma
dc.typeEditorial
dc.source.journaltitleHepatology communications
dc.source.volume2
dc.source.issue5
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4448&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3437
dc.identifier.contextkey12326406
refterms.dateFOA2022-08-23T16:45:11Z
html.description.abstract<p>Cholangiocarcinoma (CCA), a heterogeneous group of malignancy arising at any level of the biliary tree based on their anatomical location, is classified into intrahepatic (iCCA), perihilar, and distal subtypes. iCCA, which arises distally to the second‐order bile ducts, is a highly heterogeneous and aggressive malignancy with overall poor prognosis. The rate of iCCA is increasing rapidly, particularly in Western countries; however, its precise etiology and pathogenesis remain elusive.<a href="https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1189#hep41189-bib-0001">1</a> While surgical resection is the first line of treatment, liver transplantation is the potential curative treatment for unresectable tumors in patients with iCCA, and posttransplantation 5‐year survival rates are 51% in these patients. Currently, there are no curative medical therapies or targeted molecular therapies approved for use in iCCA. The complex plethora of cell types, extracellular matrix, and soluble factors that influence tumor progression should be considered to understand its pathogenesis and to devise effective strategies for its clinical management.<a href="https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1189#hep41189-bib-0001">1</a> Furthermore, identification of biomarker signatures relevant to disease progression and aggressiveness may not only aid in diagnosis but also have prognostic value that will help build a precision approach for the treatment of iCCA....</p>
dc.identifier.submissionpathoapubs/3437
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.source.pages481-483


Files in this item

Thumbnail
Name:
Mandrekar_et_al_2018_Hepatolog ...
Size:
102.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Except where otherwise noted, this item's license is described as Copyright 2018 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.